Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Inovio Pharmaceuticals Inc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.5 (market cap $3.62B), while Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M). The key difference: iShares MSCI United Kingdom (FTSE) is far larger — about 32.3× Inovio Pharmaceuticals Inc's market cap, and iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| EWU | INO | |
|---|---|---|
Market Cap | $3.62B | $112.19M |
Volume | 923,896 | 3,201,278 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $2.65 |
52-Week Low | $41.34 | $0.66 |
Typical Hold Time | 46 Days | 43 Days |
Enterprise Value | — | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU trades at $46.445, up 1.12% on the day, but faces a bearish technical outlook with 16 sell signals versus 3 buy signals. The stock is trading near key support levels at $46, with RSI indicators showing mixed signals. Recent UK market volatility driven by rising gilt yields and inflation concerns creates headwinds for this UK-focused ETF.
The outlook remains cautious given the bearish technical momentum and macroeconomic pressures from rising UK borrowing costs. Investment opportunity exists for contrarian investors if support holds, but risks include further interest rate hikes and economic uncertainty in the UK market.
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
